Mankind Pharma Gains 2.08%: 3 Key Factors Driving the Week’s Momentum

28 September: Derivatives Open Interest Surges Amid Mixed Signals

On Monday, Mankind Pharma’s stock price declined by 1.45% to close at Rs.2,439.55, slightly underperforming the Sensex which fell 1.60%. Despite this, the derivatives market showed notable activity with open interest rising 10.34% from 23,401 to 25,820 contracts. Futures volume was robust at 17,320 contracts, with a futures value of approximately ₹47,599 lakhs and options notional value at ₹5,917 crores. This increase in open interest alongside steady volume suggests fresh positions were being established rather than liquidated.

The stock traded within a narrow range, maintaining levels above key moving averages (5-day through 200-day), signalling an underlying medium- to long-term bullish trend despite short-term price softness. Delivery volumes dropped nearly 36% compared to the five-day average, indicating reduced conviction among long-term holders or profit-booking. The stock’s relative resilience versus the broader Sensex decline may have attracted speculative interest in derivatives, as traders positioned for potential rebounds or sector-specific catalysts.

29 September: Bullish Momentum Drives Call Option Activity and Price Gains

Tuesday saw a marked shift in sentiment as Mankind Pharma surged 4.32% to Rs.2,545.00, outperforming the Sensex’s 0.48% decline. The stock opened with a gap up of 3.31%, reaching an intraday high of Rs.2,516.20 during the session. This price strength was accompanied by a significant 10.7% increase in derivatives open interest, rising from 21,381 to 23,666 contracts, and a futures volume of 65,851 contracts. The total derivatives value reached ₹24,913.8 lakhs, with options alone accounting for ₹39,516.7 crores in notional value.

Call option activity was particularly notable, with 8,132 contracts traded at the 2,500 strike price on expiry day, generating a turnover of ₹19.78 crores. The open interest at this strike stood at 812 contracts, reflecting sustained bullish positioning. The stock closed near Rs.2,494.80, just shy of the 2,500 strike, underscoring market expectations of an upside breakout. Despite strong price gains, delivery volumes declined 10.17% to 2.47 lakh shares, suggesting some investors preferred leveraged derivatives exposure over outright stock purchases.

29 September: Continued Open Interest Surge and Sector Outperformance

Further reinforcing bullish sentiment on the same day, Mankind Pharma outperformed its Pharmaceuticals & Biotechnology sector, which rose a modest 0.33%, by gaining 3.87%. The stock’s intraday high of Rs.2,516.20 and a narrow trading range of Rs.2.3 indicated controlled but confident buying interest. The stock remained above all key moving averages, confirming a sustained uptrend.

The derivatives market activity was characterised by a 10.69% increase in open interest, accompanied by strong futures and options volumes. The futures segment alone accounted for ₹21,668 lakhs in value, while options contributed ₹39,516.7 crores in notional value. Despite this, delivery volumes showed a slight decline, suggesting a preference for derivatives exposure over physical holdings among some investors.

Mankind Pharma’s Mojo Score remained at 65.0 with a Hold rating, downgraded from Buy on 3 August 2026, reflecting a cautious analyst stance amid evolving market conditions. The mid-cap company’s market capitalisation stood at ₹1,03,208 crores, underscoring its significance within the sector.

1 October: Price Consolidation Amid Broader Market Weakness

On Thursday, the stock closed at Rs.2,527.00, up 0.88% from the previous day’s close, while the Sensex declined 0.99%. Volume was relatively subdued at 19,652 shares, indicating consolidation after the prior day’s strong gains. The stock maintained its position above key moving averages, signalling continued technical support despite the broader market weakness.

Key Takeaways

Positive Signals: Mankind Pharma demonstrated resilience by gaining 2.08% over the week while the Sensex declined 3.20%, highlighting relative strength. The stock’s position above all key moving averages throughout the week supports a sustained bullish technical trend. Significant increases in derivatives open interest and call option activity, particularly around the 2,500 strike price expiry, indicate strong market interest and bullish positioning among traders. The stock’s outperformance relative to its sector and the broader market underscores its leadership within the Pharmaceuticals & Biotechnology space.

Cautionary Notes: Despite bullish derivatives activity, delivery volumes declined notably on multiple days, suggesting some investors are cautious about committing to physical holdings. The Mojo Score remains at 65.0 with a Hold rating, reflecting tempered analyst optimism and signalling the need for prudence. The narrow intraday trading ranges and occasional price dips highlight potential consolidation phases and the importance of monitoring confirmation signals before aggressive positioning.

Conclusion

Mankind Pharma’s week was characterised by a complex interplay of bullish derivatives market activity and cautious investor participation in the cash segment. The stock’s 2.08% weekly gain amid a declining Sensex reflects relative strength and technical support, bolstered by robust call option volumes and rising open interest. However, the Hold Mojo Grade and declining delivery volumes counsel measured optimism. Investors and traders should continue to monitor open interest trends, price action relative to key moving averages, and post-expiry price behaviour to assess the sustainability of the current momentum. Overall, Mankind Pharma remains a noteworthy mid-cap stock with active market participation and a balanced risk-reward profile in the current environment.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today